ABSTRACT
The treatment of cancer has changed over the past centuries, moving away from the administration of broadly acting cytotoxic drugs toward the use of more specific therapies (van’t Veer and Bernards [33]). There is a shift from a “one-size” or “one- dose-fits-all” approach to a more personalized medicine. The idea behind this is to give the right dose of the right drug for the right indication for the right patient in the right time. Hamburg and Collins [12] called this approach a path to personalized medicine and described the need for the Food and Drug Administration (FDA) and National Institutes of Health (NIH) to support its growth. They gave three examples of FDA-approved drugs and diagnostics.
